The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidemic patients. A position paper by the Residual Risk Reduction Initiative (R3I) (CROSBI ID 150620)
Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija
Podaci o odgovornosti
Fruchart, J-C. ; Sacks, F. ; Hermans, M.P. ; Assmann, G. ; Brown, V.W. ; Ceska, R. ; Chapman, M.J. ; Dodson, P.M. ; Fioretto, P. ; Ginsberg, H.N. Kadowaki, T. Lablanche, J-M. ; Marx, N. ; Plutzky, J. ; Reiner, Željko ; Rosenson, R.S. ; Smith, S.C. Jr. ; Staels, B. ; Stock, J.Kk ; Sy, R. ; Wanner, C. ; Zambon, A. ; Zimmet, P.
engleski
The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidemic patients. A position paper by the Residual Risk Reduction Initiative (R3I)
Despite current standards of care aimed at achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure and glycaemia, dyslipidaemic patients remain at high residual risk of vascular events. Atherogenic dyslipidaemia, specifically elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol, often with elevated apolipoprotein B and non-HDL cholesterol, is common in patients with established cardiovascular disease, type 2 diabetes, obesity or metabolic syndrome and is associated with macrovascular and microvascular residual risk.
dyslipidaemia; residual risk
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Temeljne medicinske znanosti
